Somewhat Favorable News Coverage Somewhat Unlikely to Affect VIVUS (NASDAQ:VVUS) Stock Price

Press coverage about VIVUS (NASDAQ:VVUS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VIVUS earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.2885220873465 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of VIVUS (NASDAQ VVUS) traded up $0.03 on Thursday, hitting $0.53. 535,200 shares of the stock traded hands, compared to its average volume of 474,598. The stock has a market capitalization of $53.21, a P/E ratio of 1.61 and a beta of 0.80. VIVUS has a 1-year low of $0.48 and a 1-year high of $1.38. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86.

VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.09) EPS. sell-side analysts forecast that VIVUS will post -0.32 EPS for the current year.

Several equities analysts have commented on VVUS shares. ValuEngine lowered shares of VIVUS from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of VIVUS from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect VIVUS (NASDAQ:VVUS) Stock Price” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/12/vivus-vvus-receives-daily-media-sentiment-score-of-0-09.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Insider Buying and Selling by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply